Rose Joachim
Rose Joachim, Ph.D., is a senior healthcare and pharmaceutical analyst at GlobalData. As an analyst, she has authored numerous reports and articles analyzing market dynamics within the autoimmune, allergic, and hematological disease spaces. In 2017, Joachim earned her Ph.D. in biological sciences in public health at Harvard University. Her dissertation research explored the effects of age on immune system function during sepsis. When she wasn’t at the bench, she spent her time teaching and developing new science curricula as part of the Science Education and Academic Leadership certificate program at Harvard. Prior to her graduate studies, Joachim earned her B.S. in biology with a minor in chemistry from The College of New Jersey.
ARTICLES BY ROSE JOACHIM
-
![iStock-856877300]( "Assessing CT-P13 SC’s Impact Across Indications")
Assessing CT-P13 SC’s Impact Across Indications3/24/2021This is the second article in a two-part series exploring the anticipated competitive dynamics for Celltrion’s subcutaneous (SC) infliximab bio-better, CT-P13 SC, in the U.S.The author explores how market dynamics across different autoimmune indications will drive distinct uptake of CT-P13 SC, highlighting the potential impact on TNF inhibitor competition.
-
![Horses]( "Subcutaneous Infliximab In The U.S.: Defining CT-P13 SC’s Competitive Edge")
Subcutaneous Infliximab In The U.S.: Defining CT-P13 SC’s Competitive Edge3/17/2021TNF inhibiting biologics still reign supreme when treating immunological diseases. GlobalData believes that Celltrion’s CT-P13 SC will likely see better success than IV infliximab biosimilars in the U.S. In Part 1 of this two-part article series, we assess the factors that may give CT-P13 SC a competitive edge over Remicade and IV infliximab biosimilars.
-
![Winner Winner Chicken Dinner]( "Weighing The Potential Of Humira Biosimilars In The U.S. — Expected Winners And Losers")
Weighing The Potential Of Humira Biosimilars In The U.S. — Expected Winners And Losers10/6/2020This is the second article in a two-part series exploring the anticipated competitive landscape for Humira (adalimumab) biosimilars following their U.S. launch in 2023. In this part, we evaluate the potential for individual adalimumab biosimilar products, comparing and contrasting the agents based on a number of important factors, including order of market entry, company resources and reputation, and product characteristics.
-
![cash-cow_iStock-93824710_humira]( "Weighing The Potential Of Humira Biosimilars In The U.S.")
Weighing The Potential Of Humira Biosimilars In The U.S.9/29/2020This two-part article series explores the factors differentiating the Humira (adalimumab) biosimilar market from that of infliximab biosimilars, which could lead to stronger uptake of these products in the U.S. In Part 1, we focus on the unique competitive dynamics within the adalimumab biosimilar market.
